As patent protection approaches its final phase, the utility of interim injunctions comes under scrutiny. In Novo Nordisk v. Dr Reddy’s, the Delhi High Court holds that a credible challenge to validity, coupled with the limited remaining patent term, can outweigh claims of irreparable harm, signalling a more context-driven approach to interim relief in pharmaceutical patent disputes.